The global Alzheimer’s diagnostics and therapeutics market is expected to enjoy a valuation of US$ 6.6 Billion by the end of the year 2023, and further expand at a CAGR of 8.4% to reach a valuation of ~US$ 14.8 Billion by the year 2033. According to a recent study by Future Market Insights, diagnostics is leading the market with a share of about 54.1% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 6.1 Billion |
| Market Value 2023 | US$ 6.6 Billion |
| Market Value 2033 | US$ 14.8 Billion |
| CAGR 2023 to 2032 | 8.4% |
| Market Share of Top 5 Countries | 68.2% |
| Key Market Players | Biogen Inc., AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Novartis AG, Zydus Lifesciences Ltd, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., AMillioneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent pharmaceuticals Ltd., Unichem laboratories Ltd., and Lannett Inc. |
With the aging population and longer life expectancy, the prevalence of Alzheimer's disease is increasing worldwide. This has led to a growing demand for early and accurate diagnosis and effective treatments. Researchers are exploring personalized medicine approaches to Alzheimer's treatment, tailoring therapies to a patient's unique genetic and molecular profile. This approach may lead to more effective treatments with fewer side effects.
Overall, the market is projected to expand in the coming years, driven by an aging population and increasing demand for effective treatments, and will boost the overall growth of the Alzheimer’s diagnostics and therapeutics market during the forecast period (2022 to 2033).
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for Alzheimer’s diagnostics and therapeutics was 43.1% of the overall ~US$ 14.2 Billion of the global dementia treatment market in 2022.
The growing burden of Alzheimer's disease increased the sales of Alzheimer's diagnostics and therapeutics in the market. As the population ages and the number of people with Alzheimer's disease increases, there will likely be greater demand for diagnostic tests and treatments that can help manage the disease.
Alzheimer's disease is a progressive disease, which means that it worsens over time. Early and accurate diagnosis is critical to assisting patients and cares with treatment planning and options. A safe and reliable test that is able to precisely detect patients with amyloid plaques in Alzheimer's patients is still lacking. Recently the FDA has approved the first IVD (in vitro diagnostic test) for the early diagnosis of amyloid plaques linked with Alzheimer's disease is being marketed. The Lumipulse G-Amyloid Ratio test is designed for use in adult patients who are 55 years of age or older with cognitive impairment and are being assessed for Alzheimer's disease and other roots of cognitive decline.
Thus, advances in technology and research may lead to the development of new and more effective diagnostic tools and therapies, which could further increase the sales of these products and is expected to boost demand for the global Alzheimer’s diagnostics and therapeutics market is projected to expand at a CAGR of 8.4% during the forecast period (2023 to 2032).
The market has significant growth opportunities due to the increasing prevalence of Alzheimer's disease (AD) worldwide.
There is a growing interest in developing biomarker-based diagnostics for Alzheimer's disease. Biomarkers can help to identify individuals at risk of developing AD, track disease progression, and assess treatment response. There is a need for reliable and accurate biomarkers that can be used in clinical practice. There is a significant need for Alzheimer's diagnostics and therapeutics in emerging markets, such as Asia and Latin America, where the prevalence of the disease is increasing rapidly. Companies that can successfully penetrate these markets could see significant growth opportunities.
The market presents significant opportunities for companies that can develop innovative and effective solutions for the diagnosis and treatment of this devastating disease in both developed and developing regions will raise the market to new heights during the forecast period from 2023 to 2033.
Principal Consultant
The high cost of Alzheimer's disease diagnosis is one of the significant factors that will likely stymie the growth of the Alzheimer's disease diagnostic market. Given the resources deployed to prevent, diagnose, treat, and manage dementia, the economic costs of AD are significant for the health system. The societal costs of dementia extend beyond these direct costs, as the disease has an economic and quality-of-life impact on individuals, families, and careers.
According to some studies, the direct and indirect costs of Alzheimer's disease-related healthcare are very high. Alzheimer's disease necessitates post-mortem assessment of brain tissue via positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers, as well as several innovative clinical criteria that can aid diagnosis in patients. The cost of a true dementia diagnosis is calculated by dividing the total cost of all investigations by the number of final dementia diagnoses. The unit costs for the various components of the diagnostic process are used to assess all costs.
Aligned with the global aging population, the global prevalence of Alzheimer's disease is expected to rise exponentially in the coming decades. As a result, the costs of AD have come under increased scrutiny, and projections have been made which are restraining the growth of the Alzheimer's diagnostics and therapeutics market during the forecast period from 2023 to 2033 in the world.
With a market share of 89.7% in 2022, theUSA continue to dominate the North American region. This large market share is expected to continue throughout the forecast period.
The United States has one of the maximum prevalence rates of Alzheimer's disease in the world.
Additionally, the combination of an aging population, high prevalence of Alzheimer's disease, high healthcare spending, and strong research infrastructure make the United States an attractive market for Alzheimer's diagnostics and therapeutics.
This will result in the propulsion of demand for Alzheimer’s diagnostics and therapeutics in the country during the forecast period of 2023 to 2033.
The United Kingdom dominates the European region with a total market share of about 39.6% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
The United Kingdom has an aging population, which increases the demand for Alzheimer's diagnostics and therapeutics. As people live longer, the prevalence of Alzheimer's disease increases, and the United Kingdom is expected to see a significant rise in the number of people living with the disease in the coming years.
The United Kingdom government has shown a commitment to funding research into Alzheimer's disease, with investments in both public and private sector research. This support helps to attract investment from pharmaceutical companies, which are crucial for bringing new diagnostics and therapeutics to market and will foster profitable growth of the market over the course of the forecast period.
Japan in the East Asia region holds a market share of 60.4% in 2022 and will expand with growing numbers in the future.
Japan has a robust research infrastructure, with many leading research institutions dedicated to studying Alzheimer's disease. The country is home to a few of the world's top pharmaceutical companies, and the Japanese government has made significant investments in research and development in this area.
The aging population, strong research infrastructure, innovative technologies, and supportive government policies all suggest that Japan will continue to be an important market for Alzheimer's diagnostics and therapeutics.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Diagnostics is expected to present high growth at a CAGR of 7.5% throughout the forecast period, with a market share of 54.1% in the global market in 2022. Recent technological advancements in diagnostic testing have led to the development of more accurate and reliable tests for Alzheimer's disease. These advances have helped to increase the adoption of diagnostic testing and drive market growth.
As the demand for reliable and accurate diagnostic tests continues to grow, the market for Alzheimer's diagnostics is expected to expand significantly in the coming years.
Institutional sales hold the market share value of 57.9% during the year 2022. Institutional sales by distribution channels allow hospitals and clinics to purchase the necessary equipment and drugs needed to treat patients with Alzheimer's disease and also enable manufacturers to expand their market reach. By partnering with hospitals and clinics, manufacturers can reach a larger patient population and increase sales of their products.
Thus, institutional sales are expected to benefit the most from the sales of Alzheimer's diagnostics and therapeutics globally in the next decade.
Manufacturers invest heavily in research and development to discover new diagnostic tools and treatments for Alzheimer's disease. Some manufacturers may diversify their product offerings to include a range of diagnostic and therapeutic options for Alzheimer's disease.
Acquisitions, collaboration, and clinical trials significantly accelerate the manufacturer’s ability to capture a significant share of the market. A few of the recent instances include
| Attribute | Details |
|---|---|
| Forecast Period | 2012 to 2022 |
| Historical Data Available for | 2023 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, Israel, North Africa, and South Africa |
| Key Market Segments Covered | Product, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market will register a 9.2% CAGR through 2033.
Increasing incidences of alzheimer drive market expansion.
From 2018 to 2022, the market expanded at a 6.8% CAGR.
The United States held a market share of 94% in 2022.
By 2033, the market will reach US$ 7,359.7 million.
1. Executive Summary | Alzheimer's Diagnostics and Therapeutics Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation / Development Trends 4. Value Added Insights 4.1. Treatment Regime 4.2. Disease Epidemiology of Alzheimer’s Disease 4.3. Product Adoption/ Usage Analysis by region 4.4. Recent Product Approval 4.5. Key Promotional Strategies by Market Players 4.6. Regulatory Scenario 4.7. Pipeline Assessment 4.8. Porter’s Analysis 4.9. PESTLE Analysis 4.10. Supply Chain Analysis 4.11. Dosage Patterns 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Spending Outlook 5.1.3. Global Pharmaceutical Market Outlook 5.1.4. Global Prevalence of Dementia 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising aging population 5.2.2. Growing investment in healthcare sector 5.2.3. Growing advancement in diagnostic technologies 5.2.4. Rising prevalence of neurodegenerative diseases 5.2.5. Adverse effects may impact the market growth 5.2.6. Key Strategic Developments 5.2.7. Product Adoption Rate and Demand 5.2.8. New Product Launches 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. 2022 Market Scenario 6.2. COVID-19 and Impact Analysis 6.2.1. Revenue By Product 6.2.2. Revenue By Distribution Channel 6.2.3. Revenue By Country 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product 8.1. Introduction 8.2. Historical Market Size (US$ Million) Analysis By Product , 2012 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033 8.3.1. Therapeutics 8.3.1.1. Cholinesterase Inhibitors 8.3.1.2. NMDA Receptor Antagonists 8.3.1.3. Manufactured Combination 8.3.2. Diagnostics 8.3.2.1. Lumbar Diagnostics Test 8.3.2.2. CT Scan 8.3.2.3. MRI 8.3.2.4. EEG 8.3.2.5. PET 8.4. Market Attractiveness Analysis By Product 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Distribution Channel 9.1. Introduction 9.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 9.3.1. Institutional Sales 9.3.1.1. Hospital 9.3.1.2. Specialty Clinics 9.3.1.3. Diagnostics Centers 9.3.2. Retail Sales 9.3.2.1. Retail Pharmacies 9.3.2.2. Drug Stores 9.3.2.3. Online Pharmacies 9.4. Market Attractiveness Analysis By Distribution Channel 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region 10.1. Introduction 10.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. South Asia 10.3.5. East Asia 10.3.6. Oceania 10.3.7. Middle East & Africa 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 11.3.1. By Country 11.3.1.1. U.S. 11.3.1.2. Canada 11.3.2. By Product 11.3.3. By Distribution Channel 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Product 11.4.3. By Distribution Channel 11.5. Market Trends 11.6. Key Market Participants - Intensity Mapping 11.7. Drivers and Restraints - Impact Analysis 11.8. Country Level Analysis & Forecast 11.8.1. U.S. Market Analysis 11.8.1.1. Introduction 11.8.1.2. Market Analysis and Forecast by Market Taxonomy 11.8.1.2.1. By Product 11.8.1.2.2. By Distribution Channel 11.8.2. Canada Market Analysis 11.8.2.1. Introduction 11.8.2.2. Market Analysis and Forecast by Market Taxonomy 11.8.2.2.1. By Product 11.8.2.2.2. By Distribution Channel 12. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Mexico 12.3.1.3. Argentina 12.3.1.4. Rest of Latin America 12.3.2. By Product 12.3.3. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Product 12.4.3. By Distribution Channel 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. Brazil Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Product 12.8.1.2.2. By Distribution Channel 12.8.2. Mexico Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Product 12.8.2.2.2. By Distribution Channel 12.8.3. Argentina Market Analysis 12.8.3.1. Introduction 12.8.3.2. Market Analysis and Forecast by Market Taxonomy 12.8.3.2.1. By Product 12.8.3.2.2. By Distribution Channel 13. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. Italy 13.3.1.3. France 13.3.1.4. United kingdom 13.3.1.5. Spain 13.3.1.6. BENELUX 13.3.1.7. Russia 13.3.1.8. Nordic Countries 13.3.1.9. Rest of Europe 13.3.2. By Product 13.3.3. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Product 13.4.3. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Germany Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Product 13.8.1.2.2. By Distribution Channel 13.8.2. Italy Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Product 13.8.2.2.2. By Distribution Channel 13.8.3. France Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Product 13.8.3.2.2. By Distribution Channel 13.8.4. United kingdom Market Analysis 13.8.4.1. Introduction 13.8.4.2. Market Analysis and Forecast by Market Taxonomy 13.8.4.2.1. By Product 13.8.4.2.2. By Distribution Channel 13.8.5. Spain Market Analysis 13.8.5.1. Introduction 13.8.5.2. Market Analysis and Forecast by Market Taxonomy 13.8.5.2.1. By Product 13.8.5.2.2. By Distribution Channel 13.8.6. BENELUX Market Analysis 13.8.6.1. Introduction 13.8.6.2. Market Analysis and Forecast by Market Taxonomy 13.8.6.2.1. By Product 13.8.6.2.2. By Distribution Channel 13.8.7. Russia Market Analysis 13.8.7.1. Introduction 13.8.7.2. Market Analysis and Forecast by Market Taxonomy 13.8.7.2.1. By Product 13.8.7.2.2. By Distribution Channel 13.8.8. Nordic Countries Market Analysis 13.8.8.1. Introduction 13.8.8.2. Market Analysis and Forecast by Market Taxonomy 13.8.8.2.1. By Product 13.8.8.2.2. By Distribution Channel 14. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. India 14.3.1.2. Indonesia 14.3.1.3. Malaysia 14.3.1.4. Philippines 14.3.1.5. Thailand 14.3.1.6. Vietnam 14.3.1.7. Rest of South Asia 14.3.2. By Product 14.3.3. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product 14.4.3. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. India Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Product 14.8.1.2.2. By Distribution Channel 14.8.2. Indonesia Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Product 14.8.2.2.2. By Distribution Channel 14.8.3. Malaysia Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Product 14.8.3.2.2. By Distribution Channel 14.8.4. Philippines Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Product 14.8.4.2.2. By Distribution Channel 14.8.5. Thailand Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Product 14.8.5.2.2. By Distribution Channel 14.8.6. Vietnam Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Product 14.8.6.2.2. By Distribution Channel 15. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Product 15.3.3. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product 15.4.3. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. China Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Product 15.8.1.2.2. By Distribution Channel 15.8.2. Japan Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Product 15.8.2.2.2. By Distribution Channel 15.8.3. South Korea Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Product 15.8.3.2.2. By Distribution Channel 16. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Product 16.3.3. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. Australia Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Product 16.8.1.2.2. By Distribution Channel 16.8.2. New Zealand Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Product 16.8.2.2.2. By Distribution Channel 17. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. GCC Countries 17.3.1.2. Türkiye 17.3.1.3. Israel 17.3.1.4. North Africa 17.3.1.5. South Africa 17.3.1.6. Rest of Middle East and Africa 17.3.2. By Product 17.3.3. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. GCC Countries Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Product 17.8.1.2.2. By Distribution Channel 17.8.2. Türkiye Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Product 17.8.2.2.2. By Distribution Channel 17.8.3. Israel Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Product 17.8.3.2.2. By Distribution Channel 17.8.4. North Africa Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Product 17.8.4.2.2. By Distribution Channel 17.8.5. South Africa Market Analysis 17.8.5.1. Introduction 17.8.5.2. Market Analysis and Forecast by Market Taxonomy 17.8.5.2.1. By Product 17.8.5.2.2. By Distribution Channel 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Presence Analysis 18.2.1. Regional Footprint by Players 18.2.2. Product Footprint by Players 18.2.3. Channel Footprint by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. Biogen Inc. 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Sales Footprint 19.3.1.4. Key Financials 19.3.1.5. SWOT Analysis 19.3.1.6. Key Developments 19.3.1.7. Strategy Overview 19.3.1.7.1. Marketing Strategy 19.3.1.7.2. Product Strategy 19.3.1.7.3. Channel Strategy 19.3.2. AbbVie, Inc. 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Sales Footprint 19.3.2.4. Key Financials 19.3.2.5. SWOT Analysis 19.3.2.6. Key Developments 19.3.2.7. Strategy Overview 19.3.2.7.1. Marketing Strategy 19.3.2.7.2. Product Strategy 19.3.2.7.3. Channel Strategy 19.3.3. Teva Pharmaceuticals Ltd. 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Sales Footprint 19.3.3.4. Key Financials 19.3.3.5. SWOT Analysis 19.3.3.6. Key Developments 19.3.3.7. Strategy Overview 19.3.3.7.1. Marketing Strategy 19.3.3.7.2. Product Strategy 19.3.3.7.3. Channel Strategy 19.3.4. Eisai Co. 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Sales Footprint 19.3.4.4. Key Financials 19.3.4.5. SWOT Analysis 19.3.4.6. Key Developments 19.3.4.7. Strategy Overview 19.3.4.7.1. Marketing Strategy 19.3.4.7.2. Product Strategy 19.3.4.7.3. Channel Strategy 19.3.5. Ltd. 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Sales Footprint 19.3.5.4. Key Financials 19.3.5.5. SWOT Analysis 19.3.5.6. Key Developments 19.3.5.7. Strategy Overview 19.3.5.7.1. Marketing Strategy 19.3.5.7.2. Product Strategy 19.3.5.7.3. Channel Strategy 19.3.6. Janssen Pharmaceuticals Inc. 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Sales Footprint 19.3.6.4. Key Financials 19.3.6.5. SWOT Analysis 19.3.6.6. Key Developments 19.3.6.7. Strategy Overview 19.3.6.7.1. Marketing Strategy 19.3.6.7.2. Product Strategy 19.3.6.7.3. Channel Strategy 19.3.7. Novartis AG 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Sales Footprint 19.3.7.4. Key Financials 19.3.7.5. SWOT Analysis 19.3.7.6. Key Developments 19.3.7.7. Strategy Overview 19.3.7.7.1. Marketing Strategy 19.3.7.7.2. Product Strategy 19.3.7.7.3. Channel Strategy 19.3.8. Zydus Lifesciences Ltd. 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Sales Footprint 19.3.8.4. Key Financials 19.3.8.5. SWOT Analysis 19.3.8.6. Key Developments 19.3.8.7. Strategy Overview 19.3.8.7.1. Marketing Strategy 19.3.8.7.2. Product Strategy 19.3.8.7.3. Channel Strategy 19.3.9. Sun Pharmaceutical Industries Ltd. 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Sales Footprint 19.3.9.4. Key Financials 19.3.9.5. SWOT Analysis 19.3.9.6. Key Developments 19.3.9.7. Strategy Overview 19.3.9.7.1. Marketing Strategy 19.3.9.7.2. Product Strategy 19.3.9.7.3. Channel Strategy 19.3.10. Dr. Reddy's Laboratories Ltd. 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Sales Footprint 19.3.10.4. Key Financials 19.3.10.5. SWOT Analysis 19.3.10.6. Key Developments 19.3.10.7. Strategy Overview 19.3.10.7.1. Marketing Strategy 19.3.10.7.2. Product Strategy 19.3.10.7.3. Channel Strategy 19.3.11. Aurobindo Pharma Ltd. 19.3.11.1. Overview 19.3.11.2. Product Portfolio 19.3.11.3. Sales Footprint 19.3.11.4. Key Financials 19.3.11.5. SWOT Analysis 19.3.11.6. Key Developments 19.3.11.7. Strategy Overview 19.3.11.7.1. Marketing Strategy 19.3.11.7.2. Product Strategy 19.3.11.7.3. Channel Strategy 19.3.12. AMillioneal Pharmaceuticals Inc. 19.3.12.1. Overview 19.3.12.2. Product Portfolio 19.3.12.3. Sales Footprint 19.3.12.4. Key Financials 19.3.12.5. SWOT Analysis 19.3.12.6. Key Developments 19.3.12.7. Strategy Overview 19.3.12.7.1. Marketing Strategy 19.3.12.7.2. Product Strategy 19.3.12.7.3. Channel Strategy 19.3.13. Macleods Pharmaceuticals Ltd. 19.3.13.1. Overview 19.3.13.2. Product Portfolio 19.3.13.3. Sales Footprint 19.3.13.4. Key Financials 19.3.13.5. SWOT Analysis 19.3.13.6. Key Developments 19.3.13.7. Strategy Overview 19.3.13.7.1. Marketing Strategy 19.3.13.7.2. Product Strategy 19.3.13.7.3. Channel Strategy 19.3.14. Viatris Inc. 19.3.14.1. Overview 19.3.14.2. Product Portfolio 19.3.14.3. Sales Footprint 19.3.14.4. Key Financials 19.3.14.5. SWOT Analysis 19.3.14.6. Key Developments 19.3.14.7. Strategy Overview 19.3.14.7.1. Marketing Strategy 19.3.14.7.2. Product Strategy 19.3.14.7.3. Channel Strategy 19.3.15. Lupin Ltd. 19.3.15.1. Overview 19.3.15.2. Product Portfolio 19.3.15.3. Sales Footprint 19.3.15.4. Key Financials 19.3.15.5. SWOT Analysis 19.3.15.6. Key Developments 19.3.15.7. Strategy Overview 19.3.15.7.1. Marketing Strategy 19.3.15.7.2. Product Strategy 19.3.15.7.3. Channel Strategy 19.3.16. Cipla Ltd. 19.3.16.1. Overview 19.3.16.2. Product Portfolio 19.3.16.3. Sales Footprint 19.3.16.4. Key Financials 19.3.16.5. SWOT Analysis 19.3.16.6. Key Developments 19.3.16.7. Strategy Overview 19.3.16.7.1. Marketing Strategy 19.3.16.7.2. Product Strategy 19.3.16.7.3. Channel Strategy 19.3.17. Torrent pharmaceuticals Ltd. 19.3.17.1. Overview 19.3.17.2. Product Portfolio 19.3.17.3. Sales Footprint 19.3.17.4. Key Financials 19.3.17.5. SWOT Analysis 19.3.17.6. Key Developments 19.3.17.7. Strategy Overview 19.3.17.7.1. Marketing Strategy 19.3.17.7.2. Product Strategy 19.3.17.7.3. Channel Strategy 19.3.18. Unichem Laboratories Ltd. 19.3.18.1. Overview 19.3.18.2. Product Portfolio 19.3.18.3. Sales Footprint 19.3.18.4. Key Financials 19.3.18.5. SWOT Analysis 19.3.18.6. Key Developments 19.3.18.7. Strategy Overview 19.3.18.7.1. Marketing Strategy 19.3.18.7.2. Product Strategy 19.3.18.7.3. Channel Strategy 19.3.19. Lannett Inc. 19.3.19.1. Overview 19.3.19.2. Product Portfolio 19.3.19.3. Sales Footprint 19.3.19.4. Key Financials 19.3.19.5. SWOT Analysis 19.3.19.6. Key Developments 19.3.19.7. Strategy Overview 19.3.19.7.1. Marketing Strategy 19.3.19.7.2. Product Strategy 19.3.19.7.3. Channel Strategy 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Alzheimer's Diagnostics and Therapeutics Market
